223 related articles for article (PubMed ID: 32730786)
1. Global hepatitis C elimination: an investment framework.
Pedrana A; Howell J; Scott N; Schroeder S; Kuschel C; Lazarus JV; Atun R; Baptista-Leite R; 't Hoen E; Hutchinson SJ; Aufegger L; Peck R; Sohn AH; Swan T; Thursz M; Lesi O; Sharma M; Thwaites J; Wilson DP; Hellard M
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):927-939. PubMed ID: 32730786
[TBL] [Abstract][Full Text] [Related]
2. A global investment framework for the elimination of hepatitis B.
Howell J; Pedrana A; Schroeder SE; Scott N; Aufegger L; Atun R; Baptista-Leite R; Hirnschall G; 't Hoen E; Hutchinson SJ; Lazarus JV; Olufunmilayo L; Peck R; Sharma M; Sohn AH; Thompson A; Thursz M; Wilson D; Hellard M
J Hepatol; 2021 Mar; 74(3):535-549. PubMed ID: 32971137
[TBL] [Abstract][Full Text] [Related]
3. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
[TBL] [Abstract][Full Text] [Related]
4. A model of the economic benefits of global hepatitis C elimination: an investment case.
Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
[TBL] [Abstract][Full Text] [Related]
5. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.
Cooke GS; Andrieux-Meyer I; Applegate TL; Atun R; Burry JR; Cheinquer H; Dusheiko G; Feld JJ; Gore C; Griswold MG; Hamid S; Hellard ME; Hou J; Howell J; Jia J; Kravchenko N; Lazarus JV; Lemoine M; Lesi OA; Maistat L; McMahon BJ; Razavi H; Roberts T; Simmons B; Sonderup MW; Spearman CW; Taylor BE; Thomas DL; Waked I; Ward JW; Wiktor SZ;
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):135-184. PubMed ID: 30647010
[TBL] [Abstract][Full Text] [Related]
6. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.
Schröeder SE; Pedrana A; Scott N; Wilson D; Kuschel C; Aufegger L; Atun R; Baptista-Leite R; Butsashvili M; El-Sayed M; Getahun A; Hamid S; Hammad R; 't Hoen E; Hutchinson SJ; Lazarus JV; Lesi O; Li W; Binti Mohamed R; Olafsson S; Peck R; Sohn AH; Sonderup M; Spearman CW; Swan T; Thursz M; Walker T; Hellard M; Howell J
Liver Int; 2019 Oct; 39(10):1818-1836. PubMed ID: 31433902
[TBL] [Abstract][Full Text] [Related]
7. New WHO guidance for country validation of viral hepatitis B and C elimination.
Easterbrook P; Luhmann N; Newman M; Walsh N; Lesi O; Doherty M
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):778-780. PubMed ID: 34384530
[No Abstract] [Full Text] [Related]
8. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
10. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME
BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275
[TBL] [Abstract][Full Text] [Related]
11. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions.
Duffell EF; Hedrich D; Mardh O; Mozalevskis A
Euro Surveill; 2017 Mar; 22(9):. PubMed ID: 28277217
[TBL] [Abstract][Full Text] [Related]
12. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action.
Al Awaidy ST; Ezzikouri S
J Infect Public Health; 2020 Feb; 13(2):221-227. PubMed ID: 31445879
[TBL] [Abstract][Full Text] [Related]
13. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
[TBL] [Abstract][Full Text] [Related]
14. Progress towards elimination goals for viral hepatitis.
Cox AL; El-Sayed MH; Kao JH; Lazarus JV; Lemoine M; Lok AS; Zoulim F
Nat Rev Gastroenterol Hepatol; 2020 Sep; 17(9):533-542. PubMed ID: 32704164
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.
Day E; Hellard M; Treloar C; Bruneau J; Martin NK; Øvrehus A; Dalgard O; Lloyd A; Dillon J; Hickman M; Byrne J; Litwin A; Maticic M; Bruggmann P; Midgard H; Norton B; Trooskin S; Lazarus JV; Grebely J;
Liver Int; 2019 Jan; 39(1):20-30. PubMed ID: 30157316
[TBL] [Abstract][Full Text] [Related]
16. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
Ward JW; Hinman AR
Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
[TBL] [Abstract][Full Text] [Related]
17. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis.
Lim AG; Walker JG; Mafirakureva N; Khalid GG; Qureshi H; Mahmood H; Trickey A; Fraser H; Aslam K; Falq G; Fortas C; Zahid H; Naveed A; Auat R; Saeed Q; Davies CF; Mukandavire C; Glass N; Maman D; Martin NK; Hickman M; May MT; Hamid S; Loarec A; Averhoff F; Vickerman P
Lancet Glob Health; 2020 Mar; 8(3):e440-e450. PubMed ID: 32087176
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
[TBL] [Abstract][Full Text] [Related]
19. Investment cases for hepatitis C: never more important.
Wingrove C; Hicks J; Regan S; Wang S
Lancet Gastroenterol Hepatol; 2021 May; 6(5):340-341. PubMed ID: 33857440
[No Abstract] [Full Text] [Related]
20. Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
Palayew A; Razavi H; Hutchinson SJ; Cooke GS; Lazarus JV
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):948-953. PubMed ID: 32730784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
